Temel İstatistikler
| CIK | 1828673 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to HCW Biologics Inc.
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| May 27, 2026 |
EXHIBIT 99.1 HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commerc |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 21, 2026 |
Exhibit 99.1 HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-asso |
|
| May 21, 2026 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of May 21, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHEREAS |
|
| May 21, 2026 |
FORM OF COMMON STOCK PURCHASE WARRANT HCW BIOLOGICS INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 21, 2026 |
FORM OF REGISTRATION RIGHTS AGREEMENT Exhibt 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 21, 2026 between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser appearing on the signature page to the Purchase Agreement (as defined below) (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the C |
|
| May 21, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT Exhibit 10.3 FORM OF PLACEMENT AGENCY AGREEMENT May 21, 2026 PERSONAL AND CONFIDENTIAL HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 Attention: Hing Wong, Ph.D., Chief Executive Officer Dear Dr. Wong: This agreement (the “Agreement”) constitutes the agreement between E.F. Hutton & Co. (the “Placement Agent”) on one hand, and HCW Biologics Inc., a Delaware corporation (the “Company” |
|
| May 21, 2026 |
Exhibit 4.1 HCW BIOLOGICS INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| May 18, 2026 |
FORM OF AMENDED AND RESTATED CONSULTING AGREEMENT Exhibit 10.38 FORM OF AMENDED AND RESTATED CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to HCW Biologics Inc. (“you,” “Client” or “Company”) as more fully described in this amended and restated agreement (the “A&R Agreement”). This A&R Agreement supersedes the Consulting Agreement signed on April 25, 2026 (“Original Consulti |
|
| May 18, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT Exhibit 1.1 FORM OF PLACEMENT AGENCY AGREEMENT [●], 2026 PERSONAL AND CONFIDENTIAL HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 Attention: Hing Wong, Ph.D., Chief Executive Officer Dear Dr. Wong: This agreement (the “Agreement”) constitutes the agreement between E.F. Hutton & Co. (the “Placement Agent”) on one hand, and HCW Biologics Inc., a Delaware corporation (the “Company” and |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 14, 2026 |
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results EXHIBIT 99.1 HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results Miramar, FL – May 14, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial r |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 14, 2026 |
Exhibit 10.40 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biolo |
|
| May 13, 2026 |
As filed with the Securities and Exchange Commission on May 13, 2026 As filed with the Securities and Exchange Commission on May 13, 2026 Registration No. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2026 |
Exhibit 10.1 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to HCW Biologics Inc (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. 1. Consulting Services. (a) This |
|
| April 30, 2026 |
Exhibit 10.2 CONSULTING SERVICES AGREEMENT THIS AGREEMENT DATED AS OF April 24, 2026 BETWEEN: HCW Biologics Inc. A Delaware corporation headquartered in Miramar, Florida (hereinafter referred to as the “Firm”) -and- Bowery Consulting Group Inc. A corporation registered in the State of Florida (hereinafter referred to as the “Consultant”) A. RECITALS WHEREAS the Firm carries on business as company |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 (April 27, 2026) HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) |
|
| April 30, 2026 |
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Exhibit 99.1 HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced t |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta |
|
| April 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40591 HCW Biologics I |
|
| April 24, 2026 |
As filed with the Securities and Exchange Commission on April 24, 2026 As filed with the Securities and Exchange Commission on April 24, 2026 Registration No. |
|
| April 23, 2026 |
Exhibit 10.36 FORM OF LOCK-UP AGREEMENT [], 2026 HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 Re: Placement Agency Agreement, dated as of [], 2026 (the “Placement Agency Agreement”), between HCW Biologics Inc. (the “Company”) and E.F. Hutton & Co. (the “Placement Agent”). Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) sh |
|
| April 23, 2026 |
As filed with the Securities and Exchange Commission on April 23, 2026 As filed with the Securities and Exchange Commission on April 23, 2026 Registration No. |
|
| April 23, 2026 |
Calculation of Filing Fee Tables S-1 HCW Biologics Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| April 23, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT Exhibit 1.1 FORM OF PLACEMENT AGENCY AGREEMENT [●], 2026 PERSONAL AND CONFIDENTIAL HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 Attention: Hing Wong, Ph.D., Chief Executive Officer Dear Dr. Wong: This agreement (the “Agreement”) constitutes the agreement between E.F. Hutton & Co. (the “Placement Agent”) on one hand, and HCW Biologics Inc., a Delaware corporation (the “Company” and |
|
| April 23, 2026 |
HCW BIOLOGICS INC. FORM OF PRE-FUNDED WARRANT Exhibit 4.7 HCW BIOLOGICS INC. FORM OF PRE-FUNDED WARRANT Warrant Shares: [ ] Initial Exercise Date: [], 2026 Issue Date: [], 2026 THIS PRE-FUNDED WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “I |
|
| April 23, 2026 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.35 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [*], 2026, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser,” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| April 16, 2026 |
AMENDMENT TO AMENDED AND RESTATED BYLAWS HCW BIOLOGICS INC. Exhibit 3.2a AMENDMENT TO AMENDED AND RESTATED BYLAWS OF HCW BIOLOGICS INC. This Amendment (the “Amendment”) to the Amended and Restated Bylaws of HCW Biologics inc., a Delaware corporation (the “Corporation”), shall be, and hereby is, adopted and effective upon the unanimous written consent of the Board of Directors of the Corporation (the “Board”), approving this Amendment. WHEREAS, the Corporat |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 13, 2026 |
As confidentially submitted to the U.S. Securities and Exchange Commission on April 10, 2026. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE S |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40591 HCW Biologics I |
|
| March 31, 2026 |
Exhibit 10.36 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definiti |
|
| March 31, 2026 |
Exhibit 10.35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definiti |
|
| March 31, 2026 |
Exhibit 19.1 HCW BIOLOGICS INC. INSIDER TRADING POLICY (Adopted and approved on June 10, 2021 and as amended through March 28, 2023) 1. Purpose The following sets forth the policy of HCW Biologics Inc. (the “Company”) with respect to transactions in the Company’s securities (e.g., common stock), as well as the securities of publicly-traded companies with which the Company has a business relationsh |
|
| March 31, 2026 |
EXHIBIT 99.1 HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results Miramar, FL – March 31, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financia |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 17, 2026 |
Exhibit 99.1 HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Sta |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Sta |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 2, 2026 |
Exhibit 99.1 HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter Miramar, FL – March 2, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and dise |
|
| February 19, 2026 |
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT hcw biologics inc. FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT hcw biologics inc. Warrant Shares: Initial Exercise Date: February 19, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| February 19, 2026 |
Exhibit 99.1 HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules MIRAMAR, Fla., February 17, 2026 (GLOBE NEWSWIRE) - HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chron |
|
| February 19, 2026 |
February 17, 2026 Holder of Warrants to Purchase Common Stock issued on November 20, 2025 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-1 (File No. |
|
| February 19, 2026 |
FORM OF COMMON STOCK PURCHASE WARRANT hcw biologics inc. FORM OF COMMON STOCK PURCHASE WARRANT hcw biologics inc. Warrant Shares: Issue Date: February 19, 2026 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, . or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Shareholder Approval (a |
|
| February 19, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT February 17, 2026 FORM OF PLACEMENT AGENCY AGREEMENT February 17, 2026 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), HCW Biologics Inc. |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 19, 2026 |
FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 17, 2026, between HCW Biologics Inc. |
|
| February 19, 2026 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration Statement No. |
|
| February 17, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1(a) Exhibit 23.1a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated May 15, 2024 (except for Note 16, as to which the date is March 28, 2025), with respect to the financial statements of HCW Biologics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2024, which are incorporated by reference in this Registration Statement. |
|
| February 17, 2026 |
FORM OF SECURITIES PURCHASE AGREEMENT EX-10.41 EXHIBIT 10.41 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2026, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| February 17, 2026 |
EX-4.5 Exhibit 4.5 FORM OF COMMON STOCK PURCHASE WARRANT HCW BIOLOGICS INC. Warrant Shares: Issue Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Shareholder Approval (as |
|
| February 17, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1(b) Exhibit 23.1b CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of HCW Biologics Inc. on Form S-1 of our report dated March 28, 2025 on the balance sheet of HCW Biologics Inc. as of December 31, 2024 and the statements of operations, stockholders’ equity (deficit) and cash flows for the year ended, and to |
|
| February 17, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT EX-1.1 EXHIBIT 1.1 FORM OF PLACEMENT AGENCY AGREEMENT [ ], 2026 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), HCW Biologics Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $[ ] of units, each unit consisting of (1) eit |
|
| February 17, 2026 |
As filed with the Securities and Exchange Commission on February 17, 2026 S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 17, 2026 Registration No. |
|
| February 17, 2026 |
Calculation of Filing Fee Tables S-1 HCW Biologics Inc. Table 1: Newly Registered and Carry Forward Securities ☐ Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 13, 2026 |
Exhibit 99.1 HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune HCW Biologics receiving cash fee and co-founder shares in Trimmune valued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics’ TRBC drug development platform Initiation of Phase 1 clini |
|
| February 13, 2026 |
As filed with the Securities and Exchange Commission on February 13, 2026 S-1/A As filed with the Securities and Exchange Commission on February 13, 2026 Registration No. |
|
| February 11, 2026 |
CORRESP February 11, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HCW BIOLOGICS Inc. Registration Statement on Form S-1 File No. 333-293396 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, |
|
| February 11, 2026 |
EX-10.42 EXHIBIT 10.42 FORM OF LOCK-UP AGREEMENT , 2026 Re: Securities Purchase Agreement, dated as of , 2026 (the “Purchase Agreement”), between HCW Biologics Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) sha |
|
| February 11, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1(b) Exhibit 23.1b CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of HCW Biologics Inc. on Form S-1 of our report dated March 28, 2025 on the balance sheet of HCW Biologics Inc. as of December 31, 2024 and the statements of operations, stockholders’ equity (deficit) and cash flows for the year ended, and to |
|
| February 11, 2026 |
EX-99.1 Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to: 1.1.1 Oversee the accounting and financial |
|
| February 11, 2026 |
CORRESP February 11, 2026 VIA EDGAR AND E-MAIL Mr. James McNamara Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: HCW Biologics Inc. Registration Statement on Form S-1; Commission File No. 333-293396 Dear Mr. McNamara: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Bi |
|
| February 11, 2026 |
Calculation of Filing Fee Tables S-1 HCW Biologics Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| February 11, 2026 |
EX-99.3 Exhibit 99.3 HCW BIOLOGICS INC. RELATED PARTY TRANSACTIONS POLICY (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose HCW Biologics Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. As part of this c |
|
| February 11, 2026 |
AMENDMENT 1 TO AMENDED & RESTATED LICENSE, RESEARCH, AND CO-DEVELOPMENT AGREEMENT EX-10.43 CERTAIN INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT IN ACCORDANCE WITH ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE SUCH INFORMATION (1) IS NOT MATERIAL AND (2) IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT IS MARKED AS FOLLOWS: “[***]” TO INDICATE THE OMISSION Exhibit 10.43 AMENDMENT 1 TO AMENDED |
|
| February 11, 2026 |
EX-4.4 EXHIBIT 4.4 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT HCW BIOLOGICS INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| February 11, 2026 |
EX-99.2 Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to assist the Board in dischargin |
|
| February 11, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1(a) Exhibit 23.1a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated May 15, 2024 (except for Note 16, as to which the date is March 28, 2025), with respect to the financial statements of HCW Biologics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2024, which are incorporated by reference in this Registration Statement. |
|
| February 11, 2026 |
As filed with the Securities and Exchange Commission on February 11, 2026 S-1 Table of Contents As filed with the Securities and Exchange Commission on February 11, 2026 Registration No. |
|
| February 11, 2026 |
AMENDED & RESTATED LICENSE, RESEARCH, AND CO-DEVELOPMENT AGREEMENT EX-10.40 EXHIBIT 10.40 CERTAIN INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT IN ACCORDANCE WITH ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE SUCH INFORMATION (1) IS NOT MATERIAL AND (2) IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT IS MARKED AS FOLLOWS: “[***]” TO INDICATE THE OMISSION. AMENDED & RESTATED LIC |
|
| February 11, 2026 |
FORM OF SECURITIES PURCHASE AGREEMENT EX-10.41 EXHIBIT 10.41 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2026, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| February 11, 2026 |
北京源维 生物科技有限公司 Beijing ViGen Biotech Co. Ltd Shareholders’ Agreement EX-10.44 CERTAIN INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT IN ACCORDANCE WITH ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE SUCH INFORMATION (1) IS NOT MATERIAL AND (2) IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT IS MARKED AS FOLLOWS: “[***]” TO INDICATE THE OMISSION EXHIBIT 10.44 北京源维 生物科技有限公司 Beijing V |
|
| February 11, 2026 |
FORM OF PLACEMENT AGENCY AGREEMENT EX-1.1 EXHIBIT 1.1 FORM OF PLACEMENT AGENCY AGREEMENT [ ], 2026 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), HCW Biologics Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $[ ] shares (each a “Share” and collectively, |
|
| January 9, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1b Exhibit 23.1b CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of HCW Biologics Inc. on Form S-1 of our report dated March 28, 2025 on the balance sheet of HCW Biologics Inc. as of December 31, 2024 and the statements of operations, changes in stockholders’ equity (deficit) and cash flows for the year ende |
|
| January 9, 2026 |
EX-99.3 Exhibit 99.3 HCW BIOLOGICS INC. RELATED PARTY TRANSACTIONS POLICY (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose HCW Biologics Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. As part of this c |
|
| January 9, 2026 |
EX-99.2 Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to assist the Board in dischargin |
|
| January 9, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-23.1a Exhibit 23.1a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated May 15, 2024 (except for Note 16, as to which the date is March 28, 2025), with respect to the financial statements of HCW Biologics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2024, which are incorporated by reference in this Registration Statement. W |
|
| January 9, 2026 |
EX-99.1 Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to: 1.1.1 Oversee the accounting and financial |
|
| January 9, 2026 |
Calculation of Filing Fee Tables S-1 HCW Biologics Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| January 9, 2026 |
As filed with the Securities and Exchange Commission on January 9, 2026 S-1 Table of Contents As filed with the Securities and Exchange Commission on January 9, 2026 Registration No. |
|
| December 31, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 19, 2025 |
Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 DRS Table of Contents Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdict |
|
| November 20, 2025 |
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.1 HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) - HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic i |
|
| November 20, 2025 |
EXHIBIT 10.1 HCW Biologics Inc. November 19, 2025 Holder of Common Stock Purchase Warrants originally issued on November 20, 2024 and May 15, 2025 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: HCW Biologics Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.000 |
|
| November 20, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 19, 2025 |
FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 18, 2025 |
EXHIBIT 99.1 HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 - cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to developme |
|
| November 18, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2025 |
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results EXHIBIT 99.1 HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results Miramar, FL – November 14, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported f |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW B |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 1, 2025 |
Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 DRS Table of Contents Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdi |
|
| September 5, 2025 |
FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 18, 2025 |
Exhibit 10.16 |
|
| August 18, 2025 |
Form of Common Stock Warrant, dated May 7, 2025, between Company and Holder Exhibit 10.13 FORM OF COMMON STOCK PURCHASE WARRANT MAY 7, 2025 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFF |
|
| August 18, 2025 |
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Exhibit 99.1 HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Correction Miramar, FL – August 18, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related dis |
|
| August 18, 2025 |
Exhibit 10.14 |
|
| August 18, 2025 |
Exhibit 10.17 May 29, 2025 Exclusive License Agreement 12-month Suspension HCW Biologics Inc. (“HCW”) and Wugen, Inc. (“Wugen”) hereby mutually agree to a 12-month suspension (herein “12-month Suspension”) of Wugen’s obligations under the Exclusive License Agreement (“License”) dated December 24, 2020, between HCW and Wugen. Wugen and HCW agree to maintain the License for the 12-month Suspension p |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biolog |
|
| August 18, 2025 |
Exhibit 10.15 |
|
| August 18, 2025 |
Exhibit 10.12 HCW BIOLOGICS INC. SECOND AMENDMENT TO AmendED AND RESTATED SENIOR SECURED NOTE PURCHASE AGREEMENT and related agreements This Second Amendment to Amended and Restated Senior Secured Note Purchase Agreement and Related Agreements (this “Second Amendment”) is made as of April , 2025 (the “Effective Date”) by and between HCW Biologics Inc., a Delaware corporation (the “Company”), and e |
|
| August 15, 2025 |
Exhibit 10.1 FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT This FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT (this “First Amendment”) is made and entered into as of the 14th day of August, 2025 (the “Amendment Effective Date”) by and between HCW Biologics Inc., a Delaware corporation with a principal place of business at 2929 North Commerce Parkway, Miramar, FL 33025 (the “Company”) and Square Gate |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 15, 2025 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K For the Transit |
|
| August 14, 2025 |
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Exhibit 99.1 HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results Miramar, FL – August 14, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, toda |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 18, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 1, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 26, 2025 |
Exhibit 99.1 HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements Company in full compliance for continued listing Miramar, FL – June 26, 2025 – HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between ch |
|
| June 26, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 23, 2025 |
Exhibit 99.1 June 23, 2025 Dear Stockholder, We would like to inform you that, after the conclusion of our Annual Stockholder Meeting, our provider, Broadridge Financial Solutions Inc., advised us that it had encountered technical difficulties during the live webcast of our Meeting on June 17, 2025. Unfortunately, their issue prevented some of you from logging in and participating as we had intend |
|
| June 13, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 5, 2025 |
Exhibit 99.1 HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) - HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-re |
|
| June 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 5, 2025 |
Exhibit 99.2 HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 MIRAMAR, Fla., June 4, 2025 (GLOBE NEWSWIRE) - HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel im |
|
| June 4, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 4, 2025 |
Exhibit 99.1 HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 MIRAMAR, Fla., June 4, 2025 (GLOBE NEWSWIRE) - HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel im |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2025 |
Form of Promissory Note, dated May 8, 2025, between the Company and Holder Exhibit 10.4 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMP |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biolo |
|
| May 15, 2025 |
Amendment to Existing Warrants Agreement, dated May 13, 2025, between the Company and Purchaser Exhibit 10.3 May 13, 2025 Holder of Warrants to Purchase Common Stock issued on November 20, 2024 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-1 (File No. 333-287136) on or about the date hereof (the “Offering”) by HCW Biologics Inc. (the “Company”) of common shares, par value $0.0001 per share (the “Common Shares”), and/or other securities of |
|
| May 15, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT hcw biologics inc. Warrant Shares: Initial Exercise Date: May 15, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| May 15, 2025 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT hcw biologics inc. Warrant Shares: Initial Exercise Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| May 15, 2025 |
Form of Placement Agency Agreement, dated May 13, 2025, between Company and Maxim Group LLC Exhibit 10.1 FORM OF PLACEMENT AGENCY AGREEMENT May 13, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), HCW Biologics Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $4,999,993 of units, each unit consisting of (1) eithe |
|
| May 15, 2025 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration Statement No. 333-287136 PROSPECTUS 671,140 Units, each consisting of: One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock and Two Common Stock Warrants each to Purchase up to One Share of Common Stock 671,140 Shares of Common Stock or Shares of Common Stock Underlying Pre-Funded Warrants 1,342,28 |
|
| May 15, 2025 |
Form of Unsecured Convertible Promissory Note, dated May 5, 2025, between the Company and Holder EXHIBIT 10.6 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMP |
|
| May 15, 2025 |
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results Exhibit 99.1 HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results Miramar, FL – May 15, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today re |
|
| May 15, 2025 |
Exhibit 99.1 HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) - HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-re |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2025 |
Form of Securities Purchase Agreement, dated May 13, 2025, between the Company and Purchaser Exhibit 10.2 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 13, 2025, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2025 |
Form of amended and restated Common Stock Purchase Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 15, 2025 |
Form of Guaranty and Pledge Agreement, dated May 8, 2025, between the Dr. Hing C. Wong and Lender Exhibit 10.5 FORM OF GUARANTY AND PLEDGE AGREEMENT HCW BIOLOGICS INC., a Delaware corporation (the “Company”), is issuing that certain Promissory Note of even date herewith in the principal amount of $150,000 to [***] (the “Lender”) to memorialize the loan in such principal amount being funded by Lender to the Company on the date hereof (the “Loan”). RECITALS: WHEREAS, dr. hing c. wong (“Guarantor |
|
| May 13, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 13, 2025 As filed with the U.S. Securities and Exchange Commission on May 13, 2025 Registration No. 333-287136 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdiction |
|
| May 13, 2025 |
May 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HCWB Biologics Inc. Registration Statement on Form S-1 File No. 333-287136 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group |
|
| May 9, 2025 |
Consent of Independent Registered Public Accounting Firm (Crowe Successor) EX-23.1B Exhibit 23.1b CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of HCW Biologics Inc. on Form S-1 of our report dated March 28, 2025 on the balance sheet of HCW Biologics Inc. as of December 31, 2024 and the statements of operations, stockholders’ equity (deficit) and cash flows for the year then ended, and |
|
| May 9, 2025 |
CORRESP 1 filename1.htm May 9, 2025 VIA EDGAR AND E-MAIL Mr. Jason Drory Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: HCW Biologics Inc. Registration Statement on Form S-1; Commission File No. 333-287136 Dear Mr. Drory: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HC |
|
| May 9, 2025 |
Form of Warrant Agency Agreement Exhibit 4.7 HCW BIOLOGICS INC. and EQUINITI TRUST COMPANY, LLC as Warrant Agent Form of Warrant Agency Agreement Dated as of , 2025 FORM OF WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), between HCW Biologics Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (the “Warrant Agent”). W I T N E S S E T H WHEREAS, pursuant to a registere |
|
| May 9, 2025 |
S-1 Table of Contents Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdiction of Incorporation or Organization) Primary Standard Industrial Classification Code Numb |
|
| May 9, 2025 |
HCW Biologics Inc. Related Party Transaction Policy Exhibit 99.3 HCW BIOLOGICS INC. RELATED PARTY TRANSACTIONS POLICY (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose HCW Biologics Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitmen |
|
| May 9, 2025 |
Form of Placement Agency Agreement Exhibit 1.1 FORM OF PLACEMENT AGENCY AGREEMENT May [], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), HCW Biologics Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $ of units, each unit consisting of (1) either (i) one |
|
| May 9, 2025 |
Exhibit 107 Calculation of Fee Filing Tables Form S-1 (Form Type) HCW Biologics Inc. |
|
| May 9, 2025 |
Consent of Independent Registered Public Accounting Firm (Grant Thornton, Predecessor) EX-23.1A Exhibit 23.1a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated May 15, 2024 (except for Note 16, as to which the date is March 28, 2025), with respect to the financial statements of HCW Biologics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2024, which are incorporated by reference in this Registration Statement. W |
|
| May 9, 2025 |
Form of Securities Purchase Agreement EXHIBIT 10.35 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2025, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| May 9, 2025 |
Compensation Committee Charter of the Registrant Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to assist the Board in discharging its re |
|
| May 9, 2025 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.5 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT HCW BIOLOGICS INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| May 9, 2025 |
EXHIBIT 10.34 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COM |
|
| May 9, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.6 FORM OF COMMON STOCK PURCHASE WARRANT HCW BIOLOGICS INC. Warrant Shares: Initial Exercise Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| May 9, 2025 |
Audit Committee Charter of the Registrant Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to: 1.1.1 Oversee the accounting and financial reportin |
|
| May 9, 2025 |
EXHIBIT 10.33 HCW BIOLOGICS INC. SECOND AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED NOTE PURCHASE AGREEMENT AND RELATED AGREEMENTS This Second Amendment to Amended and Restated Senior Secured Note Purchase Agreement and Related Agreements (this “Second Amendment”) is made as of April , 2025 (the “Effective Date”) by and between HCW Biologics Inc., a Delaware corporation (the “Company”), and e |
|
| May 9, 2025 |
Exhibit 10.36 FORM OF LOCK-UP AGREEMENT , 2025 Re: Securities Purchase Agreement, dated as of , 2025 (the “Purchase Agreement”), between HCW Biologics Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings s |
|
| May 1, 2025 |
May 1, 2025 Hing Wong Chief Executive Officer HCW Biologics Inc. 2929 N Commerce Parkway Miramar, FL 33025 Re: HCW Biologics Inc. Draft Registration Statement on Form S-1 Submitted April 28, 2025 CIK No. 0001828673 Dear Hing Wong: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business da |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2025 |
Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 Table of Contents Confidential Treatment Requested by HCW Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdictio |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40591 HCW Biologics I |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 16, 2025 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-286409 PROSPECTUS Resale of up to $40,000,000 in Shares of Common Stock, and up to a total of 7,101,615 Shares of Common Stock This prospectus relates to the proposed resale by the respective selling stockholders identified below of up to the following respective amounts of shares of our common stock, par value $0.0001 per sha |
|
| April 15, 2025 |
April 15, 2025 VIA EDGAR AND E-MAIL Mr. Jason Drory Office of Life Sciences Division of Corporate Finance U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549-7010 Re: HCW Biologics Inc. Registration Statement on Form S-1; Commission File No. 333-286409 Dear Mr. Drory: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the |
|
| April 14, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 8, 2025 |
April 8, 2025 Hing Wong Chief Executive Officer HCW Biologics Inc. 2929 N Commerce Parkway Miramar, FL 33025 Re: HCW Biologics Inc. Registration Statement on Form S-1 Filed April 7, 2025 File No. 333-286409 Dear Hing Wong: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind |
|
| April 7, 2025 |
Compensation Committee Charter of the Registrant Exhibit 99.2 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to assist the Board in discharging its re |
|
| April 7, 2025 |
Exhibit 107 Calculation of Fee Filing Tables Form S-1 (Form Type) HCW Biologics Inc. |
|
| April 7, 2025 |
Consent of Independent Registered Public Accounting Firm (Crowe Successor) EX-23.1b Exhibit 23.1b CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of HCW Biologics Inc. on Form S-1 of our report dated March 28, 2025 on the balance sheet of HCW Biologics Inc. as of December 31, 2024 and the statements of operations, stockholders’ equity (deficit) and cash flows for the year ended, and to t |
|
| April 7, 2025 |
Audit Committee Charter of the Registrant Exhibit 99.1 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF HCW BIOLOGICS INC. (Adopted and approved on June 10, 2021 and effective as of the Company’s initial public offering) 1. Purpose 1.1 The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of HCW Biologics Inc. (the “Company”) shall be to: 1.1.1 Oversee the accounting and financial reportin |
|
| April 7, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| April 7, 2025 |
Consent of Independent Register Public Accounting Firm (Grant Thornton, Predecessor) EX-23.1a Exhibit 23.1a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated May 15, 2024 (except for Note 16, as to which the date is March 28, 2025), with respect to the financial statements of HCW Biologics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2023, which are incorporated by reference in this Registration Statement. W |
|
| April 1, 2025 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 1, 2025 |
Exhibit 3.1b STATE OF DELAWARE CERTIFICATE OF CORRECTION |
|
| April 1, 2025 |
HCW Biologics Announces 1-for-40 Reverse Stock Split Exhibit 99.1 HCW Biologics Announces 1-for-40 Reverse Stock Split Miramar, FL – April 1, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Dir |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 1, 2025 |
Certificate of Amendment of Certificate of Incorporation, filed March 31, 2025. Exhibit 3.1a STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That by a unanimous consent in lieu of a special meeting of the Board of Directors of HCW Biologics Inc. resolutions were duly adopted setting forth a proposed amendment |
|
| March 28, 2025 |
License, Research and Co-Development Agreement with WY Biotech dated November 17, 2024 Exhibit 10.27 LICENSE, RESEARCH, AND CO-DEVELOPMENT AGREEMENT This License, Research, and Co-Development Agreement (this “Agreement”) is made and entered into as of the 17th day of November, 2024 (the “Effective Date”) by and between HCW Biologics Inc., a Delaware corporation with a principal place of business at 2929 North Commerce Parkway, Miramar, Florida 33025 (“Licensor”) and WY Biotech Co., |
|
| March 28, 2025 |
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results Exhibit 99.1 HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results Miramar, FL – March 28, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related |
|
| March 28, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 28, 2025 |
Exhibit 10.28 Letter Agreement for Principal Terms for the Amendment of the License, Research and Co-Development Agreement with WY Biotech dated March 17, 2025 and Company’s Letter to Agree and Accept dated March 19, 2025 WY Biotech Co. Ltd. 1115-1118 Tower A No. 500 Yunjin Road Xuhui, Shanghai China HCW Biologics Inc. 2929 North Commerce Parkway Miramar, FL 33025 USA Attn: Dr. Hing Wong, CEO Marc |
|
| March 28, 2025 |
Definitive Proxy Statement dated February 21, 2025, on Form 14A, including Appendices Exhibit 10.35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 AMENDMENT NO. 1 Filed by the Registrant☒ Filed by a Party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40591 HCW Biologics I |
|
| March 19, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 6, 2025 |
Exhibit 99.1 HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements Miramar, FL – March 6, 2025 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 AMENDMENT NO. 1 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 26, 2025 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 HCW Biologics Inc. |
|
| February 21, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 21, 2025 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of February 20, 2025 (the “Execution Date”), by and between HCW Biologics Inc., a corporation incorporated in the State of Delaware (the “Company”), and Square Gate Capital Master Fund, LLC – Series 4, a series limited liability company organized in the State of Delaware (the “Investor”). RE |
|
| February 21, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 20, 2025 (the “Execution Date”), is entered into by and between HCW Biologics Inc., a corporation incorporated in the State of Delaware (the “Company”), and Square Gate Capital Master Fund, LLC - Series 4, a series limited liability company organized in the State of Delaware (together |
|
| February 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 11, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2025 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 3, 2025 |
Exhibit 99.1 HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In- Human Phase 1 Clinical Trial This study will evaluate HCW9302 in patients with moderate to severe alopecia areata Miramar, FL – February 3, 2025 – HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discov |
|
| December 23, 2024 |
EXHIBIT 99.1 HCW Biologics Inc. Received NASDAQ Staff Determination Letter Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner Miramar, FL– December 23, 2024 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discover |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 22, 2024 |
HCWB / HCW Biologics Inc. / Wong Hing C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* HCW BIOLOGICS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 40423R 105 (CUSIP Number) Hing C Wong, Ph.D. HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 (954) 842-2024 (Name, Address and T |
|
| November 20, 2024 |
Subject to completion, dated November 20, 2024 Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-266991 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 20, 2024 |
Form of Pre-Funded Common Stock Purchase Warrant between the Company and Holder Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT HCW Biologics Inc. Warrant Shares: Initial Exercise Date: November , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| November 20, 2024 |
Exhibit 99.2 HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future |
|
| November 20, 2024 |
Placement Agency Agreement, dated November 18, 2024, between the Company and Maxim Group LLC. Exhibit 10.1 PLACEMENT AGENCY AGREEMENT November 18, 2024 Dr. Hing C. Wong Chief Executive Officer HCW Biologics Inc. 2929 N. Commerce Parkway Miramar, FL 33025 Dear Dr. Wong: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and HCW Biologics Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the exclusive pl |
|
| November 20, 2024 |
Securities Purchase Agreement, dated November 18, 2024, between the Company and Purchaser Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 18, 2024, between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| November 20, 2024 |
Exhibit 99.1 HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) - HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he |
|
| November 20, 2024 |
Form of Common Stock Purchase Warrant between the Company and Holder Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2024 |
Exhibit 10.6 CERTAIN INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT IN ACCORDANCE WITH ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE SUCH INFORMATION (1) IS NOT MATERIAL AND (2) IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT IS MARKED AS FOLLOWS: “XXXXXXXXXX” TO INDICATE THE OMISSION. SETTLEMENT AGREEMENT AND RE |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2024 |
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights Miramar, FL– November 14, 2024 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today |
|
| November 14, 2024 |
Exhibit 10.5 HCW BIOLOGICS INC. FIRST AMENDMENT TO AmendED AND RESTATED SENIOR SECURED NOTE PURCHASE AGREEMENT This First Amendment to Amended and Restated Senior Secured Note Purchase Agreement(this “Amendment”) is made as of September 30, 2024 (the “Effective Date”) by and between HCW Biologics Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit B attached |
|
| September 20, 2024 |
Letter from Grant Thornton dated September 20, 2024. Exhibit 16.1 Submitted on Letterhead for Grant Thornton LLP 801 Brickell Ave., Suite 2450 Miami, FL33131-4943 September 20, 2024 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: HCW Biologics Inc. File No. 001-40591 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of HCW Biologics Inc. dated September 20, 2024, and agree with the |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 23, 2024 |
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Correction This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as pre |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biol |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 14, 2024 |
Exhibit 10.4 AMENDED AND RESTATED ESCROW AGREEMENT THIS AMENDED AND RESTATED ESCROW AGREEMENT dated as of July 2, 2024 (as the same may be amended, supplemented and/or otherwise modified from time to time, the “Escrow Agreement”), is made and entered into by and among the Noteholders listed on “Exhibit A” attached to this Escrow Agreement as secured parties as such Exhibit may be amended from time |
|
| August 14, 2024 |
Form of Senior Secured Promissory Note by and between the Company and the Holder party thereof Exhibit 10.2 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMP |
|
| August 14, 2024 |
Exhibit 10.1 HCW BIOLOGICS INC. AmendED AND RESTATED SENIOR SECURED NOTE PURCHASE AGREEMENT This Amended and Restated Senior Secured Note Purchase Agreement (this “Agreement”) is made as of July 2, 2024 (the “Closing Date”) by and between HCW Biologics Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit B attached to this Agreement (each a “Purchaser” and tog |
|
| August 14, 2024 |
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights Miramar, FL– August 14, 2024 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today |
|
| August 14, 2024 |
Exhibit 10.3 AMENDED AND RESTATED PLEDGE AGREEMENT This AMENDED AND RESTATED PLEDGE AGREEMENT, dated as of July 2, 2024 (as the same may be amended, supplemented and/or otherwise modified from time to time, this “Agreement”), is entered into by and between HCW BIOLOGICS INC., a Delaware Corporation (“Grantor”), Mercedes M. Sellek, P.A., a Florida corporation (together with its assigns, the “Escrow |
|
| August 12, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4 |
|
| May 15, 2024 |
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights Miramar, FL – May 15, 2024 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today rep |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4 |
|
| May 15, 2024 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. FORM OF COMMON STOCK SUBSCRIPTION AGREEMENT THIS COMMON STOCK SUBSCRIPTION AGREEMENT (this "Agreement") is made as of the date set forth on the signature page hereof between HCW BIOLOGICS INC., |
|
| May 15, 2024 |
4131-2309-9215.4 EXHIBIT 10.1 HCW BIOLOGICS INC. SENIOR SECURED NOTE PURCHASE AGREEMENT This Senior Secured Note Purchase Agreement (this “Agreement”) is made as of March 28, 2024 (the “Closing Date”) by and between HCW Biologics Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit B attached to this Agreement (each a “Purchaser” and together the “Purchasers”) |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40591 HCW Biolo |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 03, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 HCW Biologics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40591 82-5024477 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
